CompletedNot Applicable

Treatment of Transcranial Alternating Current Stimulation（tACS）on Cerebellar Ataxia

China164 participantsStarted 2022-08-07

Plain-language summary

This is a longitudinal, triple-blind, randomized-controlled, prospective interventional study assessing patients with cerebellar ataxia, including spinocerebellar ataxia type 3 (SCA3) and multiple system atrophy-cerebellar type (MSA-C), to examine the efficacy, safety, and tolerability of transcranial alternating current stimulation (tACS) for up to 3 months.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Patients who have concomitant epilepsy.
✕. Patients with a serious cognitive disorder, behavioral disorder, or mental illness
✕. Patients with a history of seizures, stroke, encephalitis, or other degenerative neurological diseases
✕. Patients with a serious medical disease
✕. History of head injury or neurosurgical interventions.
✕. History of any metal in the head (outside the mouth).
✕. Known history of any metallic particles in the eye, implanted cardiac pacemaker, implanted neurostimulators, surgical clips (above the shoulder line), or any medical pumps.
✕. Patients who have taken other investigational products within 4 weeks before being enrolled in this clinical trial, or patients who are pregnant or breastfeeding.

What they're measuring

For Part Ⅰ (SCA3) -1

Timeframe: Baseline - 2 weeks

For Part Ⅱ (MSA-C) -1

Timeframe: Baseline - 2 weeks

Trial details

NCT IDNCT05557786

SponsorFirst Affiliated Hospital of Fujian Medical University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-03-09

View on ClinicalTrials.gov More Spinocerebellar Ataxia Type 3 trials